RxDoctor Payments Data

Fyeza Haider, MD

Gastroenterology · Indianapolis, INNPI 1376512087

Payments from drug & device makers

$10,779in general payments, 2019–2025

Across 608 payments — averaging $17.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$948
  • Johnson & Johnson$774
  • Bristol Myers Squibb$605
  • Pfizer$360
  • plus $2K from 26 others

What the payments were for

  • Food & beverage$10,71599%
  • Education$651%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,779 in reported general payments places this provider in the 75th percentile of 323 gastroenterology providers in Indiana.

See all gastroenterology providers in Indiana

Medicare billing

Part B allowed, 2024
$66,950
Medicare patients
354
Services billed
489

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab12$484,593
LinzessLinaclotide35$32,121
SutabSod Sulf/Pot Chloride/Mag Sulf64$10,464
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates91$6,269
Budesonide EcBudesonide15$3,813
Dexlansoprazole DrDexlansoprazole17$3,674
Sucralfate21$2,145
Budesonide DrBudesonide24$1,524
Lubiprostone18$1,151
Pantoprazole Sodium51$873
Esomeprazole Magnesium23$765
Dicyclomine Hcl15$592
Famotidine26$193
Omeprazole27$56

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$774$484,59312 claims
AbbVieLinzess$3,945$32,12135 claims
Braintree Laboratories, Inc.Sutab$44$10,46464 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 323 gastroenterology providers in Indiana.

Other gastroenterology in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →